Japan Tissue Engineering Co., Ltd. (7774) AI Stock Analysis

• Market Cap: ¥32.33B
• Dividend Yield: N/A
• Average Volume (3M): 51.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: -5.65%
• EPS Growth: -469.19%
• Country: JP
• Employees: 211
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -4.56
• Shares Outstanding: 40,610,200
• 10 Day Avg. Volume: 45,190
• 30 Day Avg. Volume: 51,896
• PEG Ratio: 0.26
• Price to Book (P/B): 3.19
• Price to Sales (P/S): 7.56
• P/FCF Ratio: -82.67
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: ¥810.00 ▲(40.87% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is mainly supported by a strong, low-debt balance sheet and rapid revenue growth, but is constrained by inconsistent profitability and ongoing cash burn. Technicals show a strong uptrend, yet conditions look overextended, while valuation is weak due to current losses and no dividend support.

Positive Factors

Conservative balance sheet

A near-zero debt profile provides multi-quarter financing flexibility for R&D and commercial scaling without immediate refinancing risk. This durable strength lowers solvency risk, supports contract manufacturing commitments, and gives management time to convert growth into sustained profitability.

Strong recent revenue growth

Large, repeatable top-line gains reflect accelerating product adoption and service demand in regenerative medicine. Sustained revenue momentum expands addressable-market penetration and provides a platform to achieve operating leverage if SG&A and manufacturing efficiencies are implemented consistently.

High gross margins

Consistently high gross margins imply differentiated products and scalable manufacturing IP. That structural margin advantage allows the company to absorb elevated R&D and regulatory costs while still preserving the ability to reach operating profitability once fixed-costs are spread over higher volume.

Negative Factors

Inconsistent profitability

Profitability volatility—swinging from modest positive margins to meaningful losses—indicates earnings are sensitive to cost execution and revenue mix. This undermines the company’s ability to self-fund growth and creates uncertainty about hitting durable operating-margin targets over 2–6 months.

Weak cash generation

Repeated negative operating and free cash flow creates structural funding need: growth currently relies on external capital or equity, increasing execution risk. Persistent cash burn constrains reinvestment cadence and creates sensitivity to capital market access or partner financing over the medium term.

Returns volatility (ROE decline)

A swing to negative ROE signals that capital employed is not producing consistent returns, reflecting operational or scaling challenges. This structural variability complicates long-term planning, may hinder partner or investor confidence, and raises pressure on management to stabilize execution.

Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model

Company Description

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.

How the Company Makes Money

J-TEC generates revenue through the sale of its tissue-engineered products, which are used in medical treatments and procedures. The company's primary revenue streams come from the commercial sales of its cultured tissue products to hospitals and medical institutions. Additionally, J-TEC is involved in collaborative research and development projects with academic institutions and other corporations, which may provide additional funding and revenue opportunities. The company also invests in intellectual property development and may earn income through licensing agreements or partnerships with other entities in the regenerative medicine space.

Japan Tissue Engineering Co., Ltd. Financial Statement Overview

Summary

Strong revenue growth and a very conservative, near-zero debt balance sheet support the score, but it is held back by a return to losses in FY2025 and recurring negative operating/free cash flow, indicating the business is not yet consistently self-funding.

Income Statement

Revenue growth is a clear positive, with FY2025 revenue up ~81% year-over-year after FY2024 grew ~24%. Profitability, however, is inconsistent: FY2024 was profitable (about 5.7% net margin), but FY2025 slipped back to losses (about -10.4% net margin) and negative operating profit. Gross margin remains strong (roughly 56%–67% over recent years), but operating costs continue to pressure earnings and make results volatile.

Balance Sheet

The balance sheet is a major strength: debt is effectively zero and the company is financed primarily with equity (debt-to-equity ~0). Equity is sizeable relative to assets, supporting flexibility through down cycles. The key weakness is returns: return on equity turned negative in FY2025 after a positive FY2024, reflecting the swing back to losses rather than balance sheet leverage.

Cash Flow

Cash generation is a concern. Operating cash flow and free cash flow were negative in FY2025 (and also negative in multiple prior years), indicating the business is not yet consistently self-funding. FY2024 showed positive operating cash flow and near-breakeven free cash flow, but the rebound did not hold into FY2025, raising execution and funding-risk sensitivity despite the low-debt profile.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.44B	2.46B	2.51B	2.03B	2.10B	2.26B
Gross Profit	1.48B	1.51B	1.69B	1.14B	1.26B	1.16B
EBITDA	-74.19M	-76.02M	278.56M	-597.00M	-374.00M	-338.62M
Net Income	-286.87M	-255.30M	143.17M	-729.32M	-497.89M	-466.62M
Balance Sheet
Total Assets	6.29B	6.51B	6.99B	6.88B	7.60B	8.12B
Cash, Cash Equivalents and Short-Term Investments	3.92B	3.89B	4.27B	4.13B	4.93B	5.28B
Total Debt	0.00	0.00	0.00	133.00K	936.00K	1.74M
Total Liabilities	710.70M	687.95M	908.43M	946.15M	931.66M	954.78M
Stockholders Equity	5.58B	5.83B	6.08B	5.94B	6.67B	7.16B
Cash Flow
Free Cash Flow	0.00	-224.48M	938.00K	-798.60M	-342.48M	-473.98M
Operating Cash Flow	0.00	-148.37M	274.14M	-622.60M	-225.25M	-399.59M
Investing Cash Flow	0.00	-232.53M	-242.23M	1.12B	-116.48M	125.89M
Financing Cash Flow	0.00	-3.00K	-134.00K	-803.00K	-823.00K	-1.30M

Japan Tissue Engineering Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 575.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Positive. The current price of 575 is below the 20-day moving average (MA) of 612.60, above the 50-day MA of 570.90, and above the 200-day MA of 546.00, indicating a bullish trend. The MACD of 44.84 indicates Negative momentum. The RSI at 84.20 is Negative, neither overbought nor oversold. The STOCH value of 93.12 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7774.

Japan Tissue Engineering Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	59 Neutral	¥17.82B	-54.84	―	―	1.24%	-33.41%
7096	56 Neutral	¥9.31B	48.36	―	―	2.99%	-52.75%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥59.40B	-18.92	―	―	-82.33%	47.73%
7776	49 Neutral	¥14.17B	-11.63	―	―	-42.49%	-2.37%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%

Japan Tissue Engineering Co., Ltd. Corporate Events

Japan Tissue Engineering Widens Loss and Cuts Sales Outlook for Fiscal 2025

Japan Tissue Engineering reported non-consolidated results for the nine months to 31 December 2025 showing an 11.5% year-on-year decline in net sales to ¥1.51 billion and a deeper operating loss of ¥563 million, with net loss widening to ¥556 million as earnings per share fell to negative ¥13.70. Total assets decreased to ¥5.89 billion and equity declined, though the equity ratio remained high at 89.4%, the company maintained a zero-dividend policy for the period and full year, and it revised its full-year forecast to project a 10% drop in sales to ¥2.21 billion and a continued net loss of ¥540 million, underscoring ongoing profitability challenges despite a still-solid capital base.

The most recent analyst rating on (JP:7774) stock is a Hold with a Yen578.00 price target. To see the full list of analyst forecasts on Japan Tissue Engineering Co., Ltd. stock, see the JP:7774 Stock Forecast page.

J-TEC Wins National Insurance Coverage for Expanded JACC Use in Knee Osteoarthritis

Japan Tissue Engineering announced that its autologous cultured cartilage product JACC will be newly covered by Japan’s national health insurance for an expanded indication that now includes knee osteoarthritis, effective January 1, 2026. JACC, already approved and reimbursed for traumatic cartilage defects and osteochondritis dissecans, becomes available as an insured regenerative treatment for patients whose knee osteoarthritis symptoms do not improve with conservative therapies and who have a defined minimum cartilage defect area, with reimbursement set at 1 million yen for the tissue transport set and 1.89 million yen for the cultured cartilage package. The broader insurance coverage is expected to increase patient access to advanced cartilage repair, strengthen J-TEC’s position in orthopedic regenerative medicine, and support the company’s strategy to expand its business while enhancing clinical outcomes and quality of life for an aging population with rising knee joint disorders.